 First US leukemia patient dosed with Smart Immunes investigational SMART101 cell therapy Phase III trial will assess safety and efficacy of SMART101 in accelerating immune reconstitution to fight infection and relapse PARIS, France, January 23, 2023 Smart Immune SAS, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell therapy platform to fully and rapidly... The post First US leukemia patient dosed with Smart Immunes investigational SMART101 cell therapy appe... 